The poor prognosis for patients with advanced ovarian cancer, combined with the universal loss of tumor protein p53 (TP53) in an otherwise molecular heterogeneous background, has led to increasingly innovative approaches to treat the disease. The gene discussed is TP53; the disease is ovarian cancer.